Fortress Biotech's Network Flex Business Model

By Ben ComerChief Editor, Life Science Leader
Monday, May 1, 2023

Fortress Biotech CEO Lindsay Rosenwald talks up Fortress Biotech’s business model, which leverages partner companies to develop promising but underexposed drug candidates. Continue Reading..

The Skin Is The Game: New Ways To Play In Dermatology
5/1/2023

As the established indications in dermatology become saturated with competing products, a variety of companies, from start-ups to oncology players, are finding opportunities in underserved indications and reformulated drugs.
Hitting The Ground Running In Oncology
4/3/2023

David Lee, CEO at Servier Pharmaceuticals, talks about how he set up the French company’s U.S. division, and his goal of reaching $2 billion in annual oncology product revenue.
The Growing Appetite For Obesity Drugs
4/3/2023

New obesity drugs with unprecedented efficacy are coming into the market. Can they turn the tide in the global obesity epidemic?
U.S. Patent Expired? Why Not Grow Revenue Globally, Says Amarin
4/3/2023

Amarin is deploying a global strategy to expand patient access to Vascepa, hoping to make up for lost revenues in the U.S.
Making The Right Deal For Biohaven
3/1/2023

Biohaven CEO Vlad Coric describes the events leading up to Pfizer’s $11.6 billion acquisition, his drug launch during the start of COVID-19, and why company titles and seniority don’t really matter.
Translating Nobel Prize Winning Science Into Medicine
3/1/2023

2022 Nobel Prize winner Carolyn Bertozzi discusses her approach to translating scientific discoveries into biopharmaceutical products, and her ongoing partnership with Shasqi CEO José Mejía Oneto.
Commercialization Or Bust?
3/1/2023

If you’re a biotech in the earlier stages of clinical development, is it now incumbent upon leadership to build out the capabilities necessary for regulatory submission and commercialization, in case the right deal doesn’t materialize?
Choosing Your Battles
2/1/2023

Should business leaders speak out on the social and political issues that intermingle with the buying and selling of goods and services? Opinions vary … widely.
With Fundraising, A Track Record Matters: GeoVax's David Dodd
2/1/2023

Industry veteran David Dodd, chairman and CEO at GeoVax, answers questions about the fundraising environment for small biotechs, and the dangers of toxic warrants.

Ben Comer

Ben Comer is chief editor of Life Science Leader magazine. He has covered the biopharmaceutical, medtech and medical device industries for 15 years as a reporter and editor, and worked as a senior manager in PwC’s Health Research Institute. Comer was most recently executive editor at In Vivo magazine, where he wrote feature stories, executive profiles and articles ranging from pre-clinical biotech strategy, fundraising, supply chain, manufacturing, and regulatory issues, to global commercialization efforts, market access and environmental, social and governance topics. He has interviewed hundreds of executives and experts at biopharmaceutical and life science companies, academic institutions, law firms, patient advocacy groups, payer and provider organizations, industry trade associations and regulatory bodies. Comer has presented and moderated panels at dozens of industry conferences, convened webcasts with industry leaders, and published news articles and other writing in Scrip, Pink Sheet, MedTech Insight, Generics Bulletin, Pharmaceutical Executive, PharmTech, Applied Clinical Trials, Medical Marketing & Media and PR Week, among others. Comer is a graduate of the College of Charleston and has worked in compounding pharmacies as a certified technician. You can find him on Twitter @BenMComer.